Etoposide Market – Global Overview by Form, Application, Region and Forecast (2024-2030)

Etoposide Market size was valued at US$ 715.62 Mn. in 2023 and the total Etoposide revenue is expected to grow at 5.8% from 2024 to 2030, reaching nearly US$ 1061.89  Mn.

Etoposide Market Overview:

Etoposide, also known as Vepesid, is an anticancer medicine used to treat a variety of cancers, including prostate cancer, lung cancer, lymphoid, leukemia, neurological anomalies, and ovarian cancer. It is also applied in the treatment of hemophagocytic lymphohistiocytosis. It is taken orally or intravenously into a vein. Adverse effects are quite prevalent. Low blood cell counts, nausea, lack of appetite, diarrhea, loss of hair, and fever are some of the symptoms. Adverse reactions and hypotension are two more serious adverse effects. Consumption during pregnancy is likely to be harmful to the fetus. Etoposide belongs to the topoisomerase inhibitory class of drugs. It acts by causing DNA damage among the infected cells. It is on the WHO's List of Important Medicines.Etoposide MarketTo know about the Research Methodology:- Request Free Sample Report Etoposide prevents DNA re-ligation i.e. molecular cloning by blocking DNA topoisomerase II. This results in critical mistakes in DNA synthesis at the pre-mitotic phase of the cell cycle division, which can result in cancer cells dying. Etoposide has a cell cycle dependence and phase specificity, primarily impacting the S and G2 stages of cell growth. Etoposide's anti-tumor effect is caused by blockage of the topoisomerase II alpha variant. The medication can also suppress the beta isoform, however, blockage of this target has not been linked to anti-tumor efficacy. It is instead linked to a malignant impact. In this report, the Etoposide market's growth reasons, as well as the market's many segments (Form, Application, and Region), are discussed. Data has been given by market players, regions, and specific requirements. This market report includes a comprehensive overview of all the significant improvements that are presently prevailing in all market segments. Key data analysis is presented in the form of statistics, infographics, and presentations. The study discusses the Etoposide market's Drivers, Restraints, Opportunities, and Challenges. The report helps to assess the market growth drivers and determines how to use these drivers as a tool. The report also helps to rectify and resolve issues related to the global Etoposide market situation.

Etoposide Market Dynamics:

The primary driver of the market is the growing prevalence of prostate cancer. Prostate cancer is the second most prevalent kind of cancer among men, as per Globocan 2021 data. According to the same publication's statistics, the prevalence of prostate cancer was determined to be 1.4 million, or 7.2 % of all malignant tumors globally. Because prostate cancer is more frequent among senior citizens, the world's aging population is expected to drive the Etoposide market growth. As per the United Nations' Overall Population Aging Highlight of 2021, the worldwide older population (those aged 65 years or older) was 725 million in 2021 and is anticipated to reach 1.45 billion at the end of 2050. The high cost of cancer medications especially lung cancer medications is a major restraint for the Etoposide market growth. Lung cancer treatments are classified into four basic categories: imaging, operations, pharmaceutical aid, and indirect expenditures (such as mobility, caretaker salaries, housing, adverse effects, and lost salaries). These categories require significant expenditure from the federal govt or insurance providers, as well as added expenses borne by the patient. The high expenses of treating lung cancer have placed a significant burden on governments throughout the world as well as cancer sufferers. Despite the availability of a vast patient population, a small proportion of individuals choose costly medications to treat their ailments due to the high expenses. This is a key impediment to market growth. The lower investments in diagnostic imaging systems in developing countries cause lower cancer diagnosis rates; this is expected to hamper the growth of the market in the previously mentioned forecast period. Due to greater costs, low compensation rates, and financial restrictions, many hospitals in poorer nations are unable to invest in diagnostic imaging technology. However, because medical diagnostic treatments are in great demand in these countries, institutions that cannot manage to spend money on new imaging systems prefer to use reconditioned ones. Reconditioned systems are less expensive than newer technologies, with prices ranging from 35% to 50% of the original cost of hardware. As a result, numerous industry leaders are now marketing used gadgets through a variety of schemes.

Etoposide Market Segment Analysis:

By Application, the small cell lung cancer segment is expected to grow at a CAGR of 3.8% in the aforementioned forecast period. Etoposide has been a major and frequently utilized drug in cancer biology since its initial preclinical studies 20 years ago. Its importance in the treatment of germ cell tumors and small-cell lung disease appears unlikely to decline in the future, and its usage in non-lymphoma Hodgkin's and different high-dose treatments is anticipated to advance. The best dose and timing of etoposide are still being studied, and it is expected that these studies may result in additional improvements in its clinical efficacy in patients with sensitive malignant tumors. Ongoing clinical research might lead to the development of active etoposide-containing conjunction therapies for cervical cancer, breast cancer, and several pediatric cancers. Potential prospects include the use of etoposide in conjunction with topoisomerase I blockers, as well as the discovery of medications to reverse treatment resistance. The uses and significance of this one-of-a-kind medicine are expected to grow during the next ten years.

Etoposide Market Regional Insights:

North America (especially the US and Canada) is expected to hold a considerable market share at the end of the forecast period due to factors e.g. rising frequency of prostate cancer, increasing awareness, and increased exploration and development in this field. As per the American Cancer Society, an estimated 265,000 additional prostate cancer cases would be discovered in 2023, with 33,500 fatalities recorded in the United States. Moreover, according to the same source, around 7 out of every 10 instances are identified in males 64 and older, and it is uncommon in men under 41. Men are diagnosed at an average age of 65. The US Food and Drug Administration is making efforts to boost the growth of the chemotherapeutic industry by authorizing medications in the early phase, therefore speeding up drug outcomes. Companies and academic institutions are investing in research and development. As a result, the Etoposide market is rapidly growing in the continent. The objective of the report is to present a comprehensive analysis of the Etoposide market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Etoposide market dynamics, and structure by analyzing the market segments and projecting the Etoposide market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Etoposide market make the report investor’s guide.

Etoposide Market Scope: Inquire before buying

Global Etoposide Market
Base Year 2023 Forecast Period 2024-2030
Historical Data CAGR Market Size in 2023 Market Size in 2030
2018 to 2023 5.8% US$ 715.62 Mn US$ 1061.89 Mn
Segments Covered
by Form 1. Injection 2. Oral Use by Application 1. Small Cell Lung Cancer 2. Testicular Cancer
Regions Covered
North America 1. United States 2. Canada 3. Mexico Europe 1. UK 2. France 3. Germany 4. Italy 5. Spain 6. Sweden 7. Austria 8. Rest of Europe Asia Pacific 1. China 2. S Korea 3. Japan 4. India 5. Australia 6. Indonesia 7. Malaysia 8. Vietnam 9. Taiwan 10. Bangladesh 11. Pakistan 12. Rest of APAC Middle East and Africa 1. South Africa 2. GCC 3. Egypt 4. Nigeria 5. Rest of ME&A South America 1. Brazil 2. Argentina 3. Rest of South America

Etoposide Market Key Players

1.  Accord Healthcare Ltd. 2. Actiza Pharmaceutical Pvt. Ltd. 3. China Resources Double Crane Pharmaceutical Co. 4. Gansu Fuzheng Pharmaceutical Sci & Tech Co. 5. KPC Pharmaceuticals, Inc. 6. Mylan N.V. 7. Nippon Kayaku Co. Ltd. 8. Qilu Antibiotics Pharmaceutical Co. Ltd. 9. Shyndec Pharmaceutical Co. Ltd. 10. Teva Pharmaceutical Industries Ltd. 11. Shanghai Shyndec Pharmaceutical Co.,Ltd 12. Justesa Imagen 13. Jiangsu Hengrui 14. Cipla 15. Adley Formulations


1. Which is the potential market for the Etoposide in terms of the region? Ans. North America (especially the US and Canada) is expected to hold a considerable market share at the end of the forecast period 2. What are the restraints for new market entrants? Ans. The high cost of cancer medications especially lung cancer medications is a major restraint for the Etoposide market growth 3. What is expected to drive the growth of the Etoposide market in the forecast period? Ans. The primary driver of the market is the growing prevalence of prostate cancer. 4. What is the projected market size & growth rate of the Etoposide Market? Ans. The Etoposide Market size was valued at US$ 715.62 Mn. in 2023 and the total Etoposide revenue is expected to grow at 5.8% from 2024 to 2030, reaching nearly US$ 1061.89 Mn. 5. What segments are covered in the Etoposide Market report? Ans. The segments covered are Form, Application, and Region.
1. Global Etoposide Market: Research Methodology 2. Global Etoposide Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Etoposide Market 2.2. Summary 2.2.1. Key Findings 2.2.2. Recommendations for Investors 2.2.3. Recommendations for Market Leaders 2.2.4. Recommendations for New Market Entry 3. Global Etoposide Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • South America 3.12 COVID-19 Impact 4. Global Etoposide Market Segmentation 4.1. Global Etoposide Market, by Form (2023-2030) • Injection • Oral Use 4.2. Global Etoposide Market, by Application (2023-2030) • Small Cell Lung Cancer • Testicular Cancer 5. North America Etoposide Market(2023-2030) 5.1 North American Etoposide Market, By Form (2023-2030) • Injection • Oral Use 5.2 North America Etoposide Market, By Application (2023-2030) • Small Cell Lung Cancer • Testicular Cancer 5.3 North America Etoposide Market, by Country (2023-2030) • United States • Canada • Mexico 6. European Etoposide Market (2023-2030) 6.1. European Etoposide Market, By Form (2023-2030) 6.2. European Etoposide Market, By Application (2023-2030) 6.3 European Etoposide Market, by Country (2023-2030) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Etoposide Market (2023-2030) 7.1. Asia Pacific Etoposide Market, By Form (2023-2030) 7.2. Asia Pacific Etoposide Market, By Application (2023-2030) 7.3. Asia Pacific Etoposide Market, by Country (2023-2030) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 8. Middle East and Africa Etoposide Market (2023-2030) 8.1. Middle East and Africa Etoposide Market, By Form (2023-2030) 8.2. Middle East and Africa Etoposide Market, By Application (2023-2030) 8.3. Middle East and Africa Etoposide Market, by Country (2023-2030) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. South America Etoposide Market (2023-2030) 9.1. South America Etoposide Market, By Form (2023-2030) 9.2. South America Etoposide Market, By Application (2023-2030) 9.3 South America Etoposide Market, by Country (2023-2030) • Brazil • Argentina • Rest Of South America 10. Company Profile: Key players 10.1 Accord Healthcare Ltd. 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2 Actiza Pharmaceutical Pvt. Ltd. 10.3 China Resources Double Crane Pharmaceutical Co. 10.4 Gansu Fuzheng Pharmaceutical Sci & Tech Co. 10.5 KPC Pharmaceuticals, Inc. 10.6 Mylan N.V. 10.7 Nippon Kayaku Co. Ltd. 10.8 Qilu Antibiotics Pharmaceutical Co. Ltd. 10.9 Shyndec Pharmaceutical Co. Ltd. 10.10 Teva Pharmaceutical Industries Ltd. 10.11 Shanghai Shyndec Pharmaceutical Co.,Ltd 10.12 Justesa Imagen 10.13 Jiangsu Hengrui 10.14 Cipla 10.15 Adley Formulations